Global Rumination Syndrome Market Size, Share, Forecast Report, 2020-2027

Global rumination syndrome market is expected to grow at a CAGR of 6.1% during the forecast period. The market is majorly driven by the increasing prevalence of smoking population and rising cases of reflux disorders during pregnancy. Smoking may cause dryness of the mouth thus leading to less production of saliva, which may induce symptoms of heartburn. As saliva offsets the acid, a cigarette makes it harder for the body to guard against these acids which is some of the causes of the rumination syndrome. Additionally, factors such as increasing government and private funding to support research activities are likely to boost the market growth during the forecast period, 2018–2023.

However, the presence of misbranded and spurious drugs may hamper the growth of the market during the assessment period 2018–2023. Moreover, the presence of a number of market players and the saturation in the market have increased the introduction of many misbranded and spurious drugs. These drugs are either not effective or very low in potency which may negatively impact the market during the forecast period.

Market Segmentation

The global rumination syndrome market is segmented by diagnosis, treatment, and end-user. Diagnosis is further sub-segmented into esophagogastroduodenoscopy, gastric emptying, and others.

Furthermore, on the basis of treatment, the market is segmented into behavior therapy and medication. The medication segment has been sub-segmented into proton pump inhibitors and others. Proton pump inhibitors are sub-segmented into esomeprazole, omeprazole, pantoprazole, lansoprazole, dexlansoprazole, rabeprazole, and others. Based on end-user, the market is segmented into gastroenterology clinics, hospitals, research centers, and others.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American rumination syndrome market is segmented into two regions, namely, North America and South America. North America is further segmented into the U.S. and Canada. Europe is further segmented into Western Europe and Eastern Europe. Western Europe consists of countries such as Germany, the U.K., France, Spain, Italy, and the rest of Western Europe.

Key Players in the Global Rumination Syndrome Market

Some of the key players in this market are Pfizer Inc., Valent Pharmaceuticals, Medtronic, Astra Zeneca, Eisai Co. Ltd., Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, Johnson & Johnson, Bayer AG, Otsuka Pharmaceutical Co. Ltd, and others.

Rumination Syndrome Market, by Diagnosis & Treatment

• Diagnosis
• Esophagogastroduodenoscopy
• Flexible Endoscope
• Gastric Emptying
• CT scan
• Treatment
• Medication
• Proton pump inhibitors
• Esomeprazole
• Omeprazole
• Pantoprazole
• Lansoprazole
• Dexlansoprazole
• Rabeprazole
• Others

Rumination Syndrome Market, by End-User

• Gastroenterology Clinics
• Hospitals
• Research Centers
• Others